Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$97.83 USD

97.83
16,833,817

-0.40 (-0.41%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $97.76 -0.07 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (151 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

GEHC Positioned for Growth With AI, Global Expansion and Margins

by Zacks Equity Research

GE HealthCare's Q2 results highlight revenue growth, AI-driven innovation, and global expansion with margin gains and strong demand.

Zacks Equity Research

PAHC Stock Up 76.4% in a Year: What's Driving the Rally?

by Zacks Equity Research

Phibro Animal Health's 76.4% stock surge is fueled by strong sales recovery, global growth and a robust balance sheet.

Zacks Equity Research

NMTC Stock Gains as FDA Clears OneRF System for Facial Pain Treatment

by Zacks Equity Research

NeuroOne stock rallies after FDA clears its OneRF system, a minimally invasive solution targeting severe facial pain, scheduled to launch in late 2025.

Zacks Equity Research

MDT Stock Falls Despite Q1 Earnings & Revenue Beat, FY26 EPS View Up

by Zacks Equity Research

Medtronic tops on Q1 earnings and revenues, raises full-year EPS outlook, but shares dip on board changes.

Zacks Equity Research

Cooper Companies' Innovation Fuels Growth Amid Macro Headwinds

by Zacks Equity Research

COO leans on innovation and diversification to fuel growth, but fertility softness, tariffs and inventory headwinds weigh on near-term outlook.

Zacks Equity Research

Labcorp Debuts First FDA-Cleared Blood Test for Alzheimer's, Stock Up

by Zacks Equity Research

LH launches the first FDA-cleared blood test for Alzheimer's, boosting access to early diagnosis and nudging its stock higher.

Zacks Equity Research

Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks Equity Research

Accuray Stock Down as Q4 Earnings Miss Estimates, Revenues Down Y/Y

by Zacks Equity Research

ARAY stock down after Q4 earnings miss estimates, with product sales hit by tariffs and regional demand softness.

Zacks Equity Research

Reasons to Hold HealthEquity Stock in Your Portfolio for Now

by Zacks Equity Research

HQY's HSA growth, AI-driven efficiencies, and strong Q1 results fuel optimism despite data security concerns.

Zacks Equity Research

RGTI Stock Down Despite Q2 Earnings Top Estimates, Revenues Decline Y/Y

by Zacks Equity Research

Rigetti posts a narrower adjusted Q2 loss and unveils its largest quantum computer, but revenue declines 41.6% year over year.

Zacks Equity Research

Are Medical Stocks Lagging Boston Scientific (BSX) This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Sridatri Sarkar headshot

MDT Stock Trades Cheaper Than Peers Ahead of Q1 Earnings: Time to Buy?

by Sridatri Sarkar

Medtronic trades at a notable discount to peers as Q1 earnings loom, but rising costs and tariffs could test its resilience.

Zacks Equity Research

Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand

by Zacks Equity Research

GMED posts strong Q2 with earnings and revenues, boosted by the Nevro acquisition and expanded margins.

Zacks Equity Research

SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts

by Zacks Equity Research

Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.

Zacks Equity Research

3 Reasons Growth Investors Will Love Boston Scientific (BSX)

by Zacks Equity Research

Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

Reasons to Add Veeva Systems Stock to Your Portfolio for Now

by Zacks Equity Research

VEEV's strong first quarter, product innovations and strategic deals drive growth prospects despite rising costs.

Zacks Equity Research

CAH Q4 Earnings Beat Estimates, '26 EPS View Up, Stock Falls

by Zacks Equity Research

Cardinal Health's fourth-quarter fiscal 2025 results benefit from solid Medical and Other segments' revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.

Zacks Equity Research

EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up

by Zacks Equity Research

Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.

Zacks Equity Research

Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise

by Zacks Equity Research

PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.

Kinjel Shah headshot

J&J's MedTech Unit Sales Improve in Q2: Will the Upside Continue?

by Kinjel Shah

Johnson & Johnson's Q2 MedTech sales beat estimates, fueled by cardiovascular gains, surgical vision growth and new product momentum.

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Bruker's Q2 Earnings Miss Estimates, Stock Tumbles, Margins Contract

by Zacks Equity Research

BRKR's Q2 profit drops sharply, revenues decrease, and weak demand leads to guidance cuts despite cost-saving plans.

Mark Vickery headshot

Top Stock Reports for JPMorgan Chase, Chevron & Shopify

by Mark Vickery

JPMorgan Chase posts 43.9% annual gain, fueled by loan demand and high rates, but faces expense growth and asset quality concerns.

Zacks Equity Research

Inogen Stock Gains Following Q2 Earnings Beat, Revenues Up Y/Y

by Zacks Equity Research

INGN stock rises as Q2 loss narrows and revenue climbs 4% year over year, driven by strong B2B demand despite DTC and rental declines.

Zacks Equity Research

PacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises

by Zacks Equity Research

PACB stock jumps after Q2 results beat estimates, with narrow losses, rising margins, and strong global demand.